DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Monoclonal antibody

Monoclonal antibody

  • USAN Naming Guidelines for Monoclonal Antibodies |

    USAN Naming Guidelines for Monoclonal Antibodies |

  • Monoclonal Antibody Playbook

    Monoclonal Antibody Playbook

  • REGENERON PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Charter)

    REGENERON PHARMACEUTICALS, INC. (Exact Name of Registrant As Specified in Charter)

  • The Future of Antibodies As Cancer Drugs

    The Future of Antibodies As Cancer Drugs

  • CYRAMZA (Ramucirumab) Injection Label

    CYRAMZA (Ramucirumab) Injection Label

  • COVID-19 Immunotherapy: Novel Humanized 47D11 Monoclonal Antibody

    COVID-19 Immunotherapy: Novel Humanized 47D11 Monoclonal Antibody

  • Coverage of Monoclonal Antibody Products to Treat COVID-19

    Coverage of Monoclonal Antibody Products to Treat COVID-19

  • An EANM Procedural Guideline

    An EANM Procedural Guideline

  • Monoclonal Antibody Treatment for COVID-19

    Monoclonal Antibody Treatment for COVID-19

  • The Two Tontti Tudiul Lui Hi Ha Unit

    The Two Tontti Tudiul Lui Hi Ha Unit

  • Intact Versus Fragmented 99Mtc-Monoclonal Antibody Imaging of Infection in Patients with Septically Loosened Total Knee Arthroplasty

    Intact Versus Fragmented 99Mtc-Monoclonal Antibody Imaging of Infection in Patients with Septically Loosened Total Knee Arthroplasty

  • CEA-Scan Package Insert

    CEA-Scan Package Insert

  • Monoclonal Antibodies in Cancer Therapy

    Monoclonal Antibodies in Cancer Therapy

  • Cyramza, INN-Ramucirumab

    Cyramza, INN-Ramucirumab

  • Leukoscan, INN-Sulesomab

    Leukoscan, INN-Sulesomab

  • (INN) for Biological and Biotechnological Substances

    (INN) for Biological and Biotechnological Substances

  • Obinutuzumab, a Potent Anti–B-Cell Agent, for Rituximab-Unresponsive Igm Anti-MAG Neuropathy

    Obinutuzumab, a Potent Anti–B-Cell Agent, for Rituximab-Unresponsive Igm Anti-MAG Neuropathy

  • Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis

    Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis

Top View
  • Chemical Aspects of Metal Ion Chelation in the Synthesis and Application Antibody-Based Radiotracers
  • Design and Production of Bispecific Antibodies
  • Itap Managed Care Working Group Task Team 1: Chronic
  • INN Working Document 05.179 Update 2011
  • Pdfs/EPAR/Remo Review and Guideline for Treatment
  • Ramucirumab: a New Therapy for Advanced Gastric Cancer
  • Previous Monoclonal Antibodies Policy
  • Ramucirumab) Injection, for Intravenous Use Weeks Following a Major Surgical Procedure and Until Adequate Initial U.S
  • Bi-Specific and Tri-Specific Antibodies- the Next Big Thing in Solid Tumor Therapeutics Karie Runcie1, Daniel R
  • Radiolabeling of an Anti-Carcinoembryonic Antigen Antibody Fab' Fragment (CEA-Scan) with the Positron-Emitting Radionuclide Tc-94M
  • A Fully-Human Anti- Angiopoietin-2 (Ang2) Monoclonal Antibody, in Pati
  • REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors Kyriakos P
  • Humanization of Antibodies Using a Machine Learning Approach on Large-Scale Repertoire Data
  • (INN) for Biological and Biotechnological Substances
  • UCSF COVID-19 Monoclonal Antibody Use Process Background
  • Cancer Imaging with Radiolabeled Antibodies
  • Monoclonal Antibody COVID-19 Treatment for Non-Hospitalized
  • A Phase 1B/2 Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer


© 2024 Docslib.org    Feedback